Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
1
Study Matches
A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 compared with mepolizumab or benralizumab.
Non-inferiority study of GSK3511294 compared with mepolizumab or benralizumab in participants with severe asthma with an eosinophilic phenotype.
Adults 18 years or older at the time of signing the informed consent. Have a documented diagnosis of asthma for 2 or more years. Receiving either mepolizumab or benralizumab for 12 or more months prior to screening. A well-documented requirement for regular treatment with medium to high dose inhaled corticosteroid in the 12 months prior to Visit 1 with or without maintenance oral corticosteroid. Current treatment with at least one additional controller medication, besides an inhaled corticosteroids.
Exclusion Criteria:
Concurrent respiratory disease Eosinophilic diseases Pregnancy Current or former smokers with a smoking history of 10 or more years. Active COVID-19 infection